Abstract
Glioblastoma (GBM) is a highly malignant primary brain tumor known for its invasiveness and aggressive resistance to standard treatment. It is currently the most common primary brain tumor which is associated with a high mortality rate. Tumor initiating cells (TICs) are a subpopulation of GBM stem cells which are capable of self-renewal and apoptotic resistance, and are thought to account for GBMs aggressive nature. Recent efforts have focused on therapies which target key intracellular apoptotic pathways which may confer tumor resistance, such as Akt, p53, Bcl-2 family proteins, caspase family proteases, and more recently microRNAs. Research into microRNA’s role in GBM has shown that microRNAs play a key regulatory role in the GBM apoptotic pathway, making it a potential therapeutic target. In this review we summarized the molecular mechanisms involved in the signaling pathways of human GBM TIC apoptosis and microRNAs, the contemporary treatments involving different members of the signaling cascade, and the future direction of GBM treatment strategies.
Keywords: Apoptosis, glioblastoma, microRNA, tumor initiating cells
Current Molecular Medicine
Title:Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways
Volume: 13 Issue: 3
Author(s): J. Liu, A. M. Albrecht, X. Ni, J. Yang, M. Li and Vivian L. Smith
Affiliation:
Keywords: Apoptosis, glioblastoma, microRNA, tumor initiating cells
Abstract: Glioblastoma (GBM) is a highly malignant primary brain tumor known for its invasiveness and aggressive resistance to standard treatment. It is currently the most common primary brain tumor which is associated with a high mortality rate. Tumor initiating cells (TICs) are a subpopulation of GBM stem cells which are capable of self-renewal and apoptotic resistance, and are thought to account for GBMs aggressive nature. Recent efforts have focused on therapies which target key intracellular apoptotic pathways which may confer tumor resistance, such as Akt, p53, Bcl-2 family proteins, caspase family proteases, and more recently microRNAs. Research into microRNA’s role in GBM has shown that microRNAs play a key regulatory role in the GBM apoptotic pathway, making it a potential therapeutic target. In this review we summarized the molecular mechanisms involved in the signaling pathways of human GBM TIC apoptosis and microRNAs, the contemporary treatments involving different members of the signaling cascade, and the future direction of GBM treatment strategies.
Export Options
About this article
Cite this article as:
Liu J., Albrecht A. M., Ni X., Yang J., Li M. and L. Smith Vivian, Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways, Current Molecular Medicine 2013; 13 (3) . https://dx.doi.org/10.2174/1566524011313030004
DOI https://dx.doi.org/10.2174/1566524011313030004 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Pioglitazone Prevents Smoking Carcinogen-Induced Lung Tumor Development in Mice
Current Cancer Drug Targets Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting
Current Gene Therapy Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc
Current Signal Transduction Therapy Subject Index To Volume 7
Current Drug Targets Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry LAT1 Targeted Delivery of Methionine Based Imaging Probe Derived from M(III) Metal Ions for Early Diagnosis of Proliferating Tumours using Molecular Imaging Modalities
Current Cancer Drug Targets Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism NOB1: A Potential Biomarker or Target in Cancer
Current Drug Targets Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Modulation of Poly(A)-specific Ribonuclease (PARN): Current Knowledge and Perspectives
Current Medicinal Chemistry Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells
Current Drug Delivery In Vitro Evidence for Competitive TSPO Binding of the Imaging Biomarker Candidates Vinpocetine and Two Iodinated DAA1106 Analogues in Post Mortem Autoradiography Experiments on Whole Hemisphere Human Brain Slices
Current Radiopharmaceuticals